B
Bristol-Myers Squibb Company (BMY)
NYQ – Real vaqt narxi. Valyuta: USD
56.45
+0.78 (1.40%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
56.45
+0.78 (1.40%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Bristol-Myers Squibb Company dunyo bo'ylab biofarmatsevtika mahsulotlarini kashf qiladi, ishlab chiqadi, litsenziyalaydi, ishlab chiqaradi, sotadi, tarqatadi va sotadi. U onkologiya, gematologiya, immunologiya, yurak-qon tomir tizimi, nevrologiya va boshqa sohalar uchun mahsulotlarni taklif etadi. Kompaniyaning mahsulotlari orasida turli xil saratonga qarshi ko'rsatmalarga ega bo'lgan Opdivo; qattiq o'smalar uchun teri osti PD-1 inhibitore bo'lgan Opdivo Qvantig; faol revmatoid artrit va psoriatik artrit uchun Orencia; inoperable yoki metastatik melanomali bemorlarni davolash uchun Yervoy; anemiya uchun Reblozyl; qaytalangan yoki refrakter katta B-hujayrali limfomali bemorlarni davolash uchun Breyanzi; inoperable yoki metastatik melanomani davolash uchun Opdualag; va funktsional qobiliyatni va simptomlarni yaxshilash uchun simptomatik obstruktsion HCMni davolash uchun Camzyos mavjud. Shuningdek, u ko'p sklerozning qaytalanish shakllarini davolash uchun Zeposia; qaytalangan yoki refrakter ko'p miyelomali bemorlarni davolash uchun Abecma; o'rta va og'ir darajadagi blyashka psoriazini davolash uchun Sotyktu; KRASG12C-mutatsiyali mahalliy rivojlangan yoki metastatik kichik hujayrali o'pka rakki (NSCLC) bo'lgan kattalar bemorlarni davolash uchun Krazati; va shizofreniyani davolash uchun Cobenfy taklif etadi. Bundan tashqari, u klapan bo'lmagan atriyal fibrilatsiyada insult/sistemik emboliya xavfini kamaytirish va DVT/PEni davolash uchun Eliquisni; ko'p miyelomani davolash uchun og'iz orqali yuboriladigan immunomodulyator dori bo'lgan Revlimidni; ko'p miyeloma uchun Pomalyst/Imnovidni; Filadelfiya xromosomasi-pozitiv surunkali miyeloid leykemiyasi uchun Sprycelni; va ko'krak bezi rakini davolash uchun Abraxane'ni taklif etadi. Keyinchalik, u mahalliy rivojlangan yoki metastatik ROS1-pozitiv NSCLCni davolash uchun Augtyro; va NSCLC va oshqozon osti bezi rakini taqdim etadi. U mahsulotlarni ulgurji savdogarlar, distribyutorlar, maxsus dorixonalar va kamroq darajada chakana sotuvchilar, shifoxonalar, klinikalarga va davlat muassasalariga sotadi. Kompaniya ilgari Bristol-Myers Company nomi bilan tanilgan. Kompaniya 1887 yilda tashkil etilgan va shtab-kvartirasi Nyu-Jersi shtatining Prinston shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Christopher S. Boerner Ph.D. | CEO & Chairman |
| Dr. Joseph J. Eiden Jr. | Head of Medical Affairs |
| Mr. Adam Lenkowsky | Executive VP & Chief Commercialization Officer |
| Mr. Charles E. Triano | SVP & Head of Investor Relations |
| Mr. Cristian Massacesi M.D. | Executive VP, Chief Medical Officer & Head of Development |
| Mr. David V. Elkins | Executive VP & CFO |
| Mr. Greg Meyers | Executive VP and Chief Digital & Technology Officer |
| Ms. Ahn Amanda Poole | Executive VP & Chief People Officer |
| Ms. Cari Gallman | Executive VP, General Counsel & Chief Policy Officer |
| Ms. Karin Shanahan | Executive VP, Chief Supply Chain & Operations Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-08 | S-8 | ef20072737_s8.htm |
| 2026-05-08 | 8-K | ef20072750_8k.htm |
| 2026-04-30 | 10-Q | bmy-20260331.htm |
| 2026-04-17 | DEFA14A | ef20070631_defa14a.htm |
| 2026-03-27 | 15-12G | ef20068734_1512g.htm |
| 2026-03-25 | DEFA14A | ef20067096_defa14a.htm |
| 2026-02-11 | 10-K | bmy-20251231.htm |
| 2026-02-05 | 8-K | bmy-20260205.htm |
| 2026-01-12 | 8-K | ef20062582_8k.htm |
| 2025-11-18 | 8-K | ef20059419_8k.htm |